BACKGROUND: The Canadian and American Diabetes Associations recommend the use of an oral glucose tolerance test to screen for abnormal glucose tolerance among women with polycystic ovary syndrome when their fasting plasma glucose level is 5.7 mmol/L or more (Canadian guideline) and 5.6 mmol/L or more (American). Our objective was to determine the predictive value of 5.6 mmol/L as a fasting plasma glucose cutoff for detecting abnormal glucose tolerance in women with polycystic ovary syndrome, and then to define the optimal cutoff for this population. METHODS: An oral glucose tolerance test was administered to 105 consecutive women with polycystic ovary syndrome referred to an academic reproductive endocrine clinic. We calculated sensitivity, specificity and likelihood ratios. RESULTS: The sensitivity of a 5.6 mmol/L cutoff was 48% (95% confidence interval [CI] 30%-67%); its specificity, 98.7% (95% CI 96.1%-100%). With this cutoff, 52% of women with polycystic ovary syndrome whose glucose tolerance is abnormal would be missed. The prevalence of abnormal glucose tolerance was 28%, with a positive predictive value of 93% (95% CI 81%-100%) and a negative predictive value of 83% (95% CI 76%-91%). The likelihood ratio for a positive test was 36.7 (95% CI 5.0-267), and for a negative test, 0.5 (95% CI 0.4-0.7). The optimal fasting plasma glucose cutoff value was 5.0 mmol/L, with a 79% sensitivity (95% CI 65%-94%) and 66% specificity (95% CI 55%-77%). If this cutoff were used, 24% of women with abnormal glucose tolerance would still be missed. INTERPRETATION: The Canadian and American recommendations--of screening for abnormal glucose tolerance with an oral glucose tolerance test only when the results of a fasting plasma glucose test are 5.7 mmol/L (or 5.6 mmol/L) or more--are inappropriate for women with polycystic ovary syndrome. We therefore recommend that all women with polycystic ovary syndrome have an oral glucose tolerance test.
BACKGROUND: The Canadian and American Diabetes Associations recommend the use of an oral glucose tolerance test to screen for abnormal glucose tolerance among women with polycystic ovary syndrome when their fasting plasma glucose level is 5.7 mmol/L or more (Canadian guideline) and 5.6 mmol/L or more (American). Our objective was to determine the predictive value of 5.6 mmol/L as a fasting plasma glucose cutoff for detecting abnormal glucose tolerance in women with polycystic ovary syndrome, and then to define the optimal cutoff for this population. METHODS: An oral glucose tolerance test was administered to 105 consecutive women with polycystic ovary syndrome referred to an academic reproductive endocrine clinic. We calculated sensitivity, specificity and likelihood ratios. RESULTS: The sensitivity of a 5.6 mmol/L cutoff was 48% (95% confidence interval [CI] 30%-67%); its specificity, 98.7% (95% CI 96.1%-100%). With this cutoff, 52% of women with polycystic ovary syndrome whose glucose tolerance is abnormal would be missed. The prevalence of abnormal glucose tolerance was 28%, with a positive predictive value of 93% (95% CI 81%-100%) and a negative predictive value of 83% (95% CI 76%-91%). The likelihood ratio for a positive test was 36.7 (95% CI 5.0-267), and for a negative test, 0.5 (95% CI 0.4-0.7). The optimal fasting plasma glucose cutoff value was 5.0 mmol/L, with a 79% sensitivity (95% CI 65%-94%) and 66% specificity (95% CI 55%-77%). If this cutoff were used, 24% of women with abnormal glucose tolerance would still be missed. INTERPRETATION: The Canadian and American recommendations--of screening for abnormal glucose tolerance with an oral glucose tolerance test only when the results of a fasting plasma glucose test are 5.7 mmol/L (or 5.6 mmol/L) or more--are inappropriate for women with polycystic ovary syndrome. We therefore recommend that all women with polycystic ovary syndrome have an oral glucose tolerance test.
Authors: Joan C Lo; Seth L Feigenbaum; Jingrong Yang; Alice R Pressman; Joe V Selby; Alan S Go Journal: J Clin Endocrinol Metab Date: 2006-01-24 Impact factor: 5.958
Authors: David A Ehrmann; David R Liljenquist; Kristen Kasza; Ricardo Azziz; Richard S Legro; Mahmoud N Ghazzi Journal: J Clin Endocrinol Metab Date: 2005-10-25 Impact factor: 5.958
Authors: E S Knochenhauer; T J Key; M Kahsar-Miller; W Waggoner; L R Boots; R Azziz Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: Ian Blumer; Eran Hadar; David R Hadden; Lois Jovanovič; Jorge H Mestman; M Hassan Murad; Yariv Yogev Journal: J Clin Endocrinol Metab Date: 2013-11 Impact factor: 5.958